JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60
JP Morgan analyst Priyanka Grover initiates coverage on Neurogene (NASDAQ:NGNE) with a Overweight rating and announces Price Target of $60.
Share
Why It Matters
A big bank analyst just started watching Neurogene and thinks it looks good. This means the analyst believes the company has promise, so watch if other experts agree.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.